What is lymphoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Lymphoma?

Lymphoma is a group of malignant cancers arising from lymphocytes (white blood cells), broadly classified into two main types: Hodgkin lymphoma and non-Hodgkin lymphoma, which together represent a heterogeneous collection of over 90 distinct subtypes with varying biological behaviors, treatments, and prognoses 1, 2, 3.

Classification and Types

Lymphoma divides into two major categories:

Hodgkin Lymphoma (HL)

  • Accounts for approximately 5-11% of all lymphomas in Western countries 1, 2, 3
  • Incidence: 2-3 per 100,000 annually, resulting in approximately 8,720 new U.S. cases in 2025 1, 2
  • Shows a bimodal age distribution: peak in the third decade of life, with a second smaller peak after age 55 1

Two distinct subtypes exist 1, 2:

  1. Classical Hodgkin Lymphoma (CHL) - 95% of cases

    • Characterized by Reed-Sternberg cells (CD15+/CD30+/CD20–)
    • Four histologic variants: nodular sclerosis, mixed cellularity, lymphocyte-depleted, and lymphocyte-rich
  2. Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) - 5% of cases

    • Contains lymphocytic-histiocytic (L&H) "popcorn" cells with different immunophenotype (CD15–/CD30–/CD20+)

Non-Hodgkin Lymphoma (NHL)

  • Represents approximately 89-95% of all lymphomas 3, 4
  • Approximately 55,000-60,000 new U.S. cases annually 4
  • 90% are B-cell origin; 10% are T-cell origin 4
  • Most common subtypes: follicular lymphoma and diffuse large B-cell lymphoma 4

Pathologic Characteristics

A unique feature of Hodgkin lymphoma is that malignant cells (Hodgkin-Sternberg cells) represent only 0.1-1% of the entire cell population, with the remainder consisting of a heterogeneous inflammatory infiltrate including lymphocytes, histiocytes, eosinophils, plasma cells, and fibroblasts 1.

Follicular lymphoma typically harbors the t(14;18) chromosomal translocation, resulting in BCL-2 protein overexpression, with common mutations in chromatin-modifying genes 5.

Clinical Presentation

Most patients (>60%) with Hodgkin lymphoma initially present with painless enlarged cervical lymph nodes 1.

Key clinical features include 1, 6, 3:

  • Painless lymphadenopathy (most common presentation)
  • B symptoms (present in ~35% of cases): fever, drenching night sweats, unexplained weight loss >10% in 6 months
  • Alcohol-induced pain at disease sites (specific to HL)
  • Pruritus and fatigue
  • Most common sites: cervical, supraclavicular, and mediastinal lymph nodes

Lymphoma can involve 1, 6:

  • Lymph nodes (primary)
  • Spleen, liver, bone marrow
  • Lung and other extranodal sites (less common in HL, more common in certain NHL subtypes)

Diagnosis

Lymph node biopsy is mandatory for diagnosis 1, 6. An excisional or core needle biopsy is required; fine needle aspiration alone is insufficient 6, 3.

Immunohistochemistry is highly recommended to determine:

  • Cell lineage (B-cell vs T-cell)
  • Specific immunophenotype markers
  • Clonality assessment 6

Prognosis

Hodgkin lymphoma is among the most curable malignancies, with cure rates exceeding 95% for early favorable disease and 5-year survival of 81% overall 2, 7, 8. The primary treatment consideration has shifted from achieving cure to minimizing long-term toxicity 2.

Non-Hodgkin lymphomas show marked heterogeneity: follicular lymphoma patients often achieve median overall survival exceeding 15-20 years, while aggressive subtypes like diffuse large B-cell lymphoma require intensive treatment but can achieve cure in 30-50% of advanced cases 5, 4.

Common pitfall: Histologic transformation of indolent lymphomas (particularly follicular lymphoma) to aggressive subtypes occurs in 2-3% annually and significantly worsens prognosis 5.

References

Guideline

hodgkin lymphoma, version 1.2026, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2026

Research

Lymphoma: Diagnosis and Treatment.

American family physician, 2020

Research

Non-Hodgkin lymphoma: diagnosis and treatment.

Mayo Clinic proceedings, 2005

Guideline

hodgkin lymphoma.

Journal of the National Comprehensive Cancer Network : JNCCN, 2011

Research

Hodgkin lymphoma.

Critical reviews in oncology/hematology, 2013

Research

Hodgkin Lymphoma: Diagnosis and Treatment.

Mayo Clinic proceedings, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.